Proactiveinvestors recommends
Additional Information
Market: LSE
Sector: Pharmaceuticals
EPIC: ATD
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
BioSeek
www.bioseekinc.com

BioSeek, an Asterand company, is improving the success rate of pharmaceutical research and development by integrating human biology from the earliest stages of drug discovery onward. Our BioMAP® Systems incorporate predictive primary human cell-based disease models that generate uniquely informative biological activity profiles for each potential drug. As a result, our technology drives the selection and development of new drug candidates. We leverage our BioMAP® Systems technology in collaborations to enhance the productivity of our pharmaceutical partners' pipelines to identify promising compounds for therapeutic development.

Full BioSeek profile here
Pdf

Asterand subsidiary achieves “research milestone” with Japanese partner

30th Nov 2011, 11:13 am by Jon Mainwaring

 

Human tissue specialist Asterand (LON:ATD) announced today that its BioSeek subsidiary has achieved a “research milestone” in its drug discovery collaboration with Japanese pharmaceutical firm Ono Pharmaceutical.

BioSeek is applying its BioMAP platform to perform a number of tasks on a drug discovery target selected by Ono. These tasks include phenotypic screening, hit identification, lead optimisation and clinical candidate selection.

Under the three-year agreement with Ono, BioSeek is receiving research funding and is eligible to receive success payments based on the research-phase progress of this collaboration and further milestone payments based on the clinical development-phase progress of a drug candidate discovered under this collaboration. Ono will have worldwide rights to develop and sell all pharmaceutical products discovered through the collaboration.

“We highly value our relationship with Ono since it enables us to take full advantage of BioMAP'’s power to discover and develop innovative new drug candidates,” said Jack Davis, Asterand’s chairman and chief executive officer. “We are looking forward to the successful continuation and further achievements of the collaboration.”

Asterand is a supplier of high-quality human tissue and tissue-based services. It takes a “comprehensive approach” to human tissue and associated research services, which it says offers pharmaceutical, biotech and diagnostic companies a “unique opportunity” to have one company meet all of their human biomaterial needs.


 

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here